Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2025.1613095 Immunology Correction Corrigendum: Harnessing single-cell and multi-omics insights: STING pathway-based predictive signature for immunotherapy response in lung adenocarcinoma Ding Yang 1 † Wang Dingli 2 † Yan Dali 3 † Fan Jun 4 † Ding Zongli 5 * Xue Lei 4 * 1 Department of Pathology, Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, China 2 Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China 3 Department of Oncology, The Affiliated Huai’an Hospital of Xuzhou Medical University and the Second People’s Hospital of Huai’an, Huai’an, China 4 Department of Thoracic Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China 5 Department of Geriatrics, The Affiliated Huai’an Hospital of Xuzhou Medical University and the Second People’s Hospital of Huai’an, Huai’an, China

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Zongli Ding, zongliding2011@126.com; Lei Xue, leixue1385@njmu.edu.cn

†These authors have contributed equally to this work and share first authorship

 30 04 2025 2025 16 1613095 16 04 2025 17 04 2025 Copyright © 2025 Ding, Wang, Yan, Fan, Ding and Xue 2025 Ding, Wang, Yan, Fan, Ding and Xue

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Harnessing single-cell and multi-omics insights: STING pathway-based predictive signature for immunotherapy response in lung adenocarcinoma by Yang D, Wang D, Yan D, Fan J, Ding Z and Xue L (2025). Front. Immunol. 16:1575084. doi: 10.3389/fimmu.2025.1575084 non-small cell lung cancer lung adenocarcinoma single-cell RNA sequencing prognosis signature machine learning section-in-acceptance Cancer Immunity and Immunotherapy

In the original article, there was an error in the author list. The first author’s name was incorrectly listed as “Ding Yang” instead of the correct name “Yang Ding”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.